PULmonary DAMage after hospitalization for acute COvid-19 (PULDAMCO), an exploratory prospective cohort study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON23357

Enrollment

150

Registered

2020-07-07

Start date

2020-07-07

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

CT angiography at 3 months and chest CT low dose at 12 months after acute COVID-19 infection

Eligibility

Inclusion criteria

Inclusion criteria: ? Hospital admission for COVID-19 ? CT during admission with CO-RADS >=3 ? Informed consent

Exclusion criteria

Exclusion criteria: ? Age < 18 ? Pregnancy ? Renal failure (MDRD < 30 ml/kg/1,73m^2) ? Allergic reaction to iodine containing intravenous contrast media

Design outcomes

Primary

Measure	Time frame
-Prevalence of residual lung damage (per type) at 3 and 12 month -Estimated percentage of lung parenchyma affected by various types of diffuse lung damage (e.g., ground glass, consolidation, perfusion abnormalities) -Number of lung segments affected by focal lung damage (e.g., traction bronchiectasis, residual lung emboli) -Predictors of pulmonary damage after acute COVID-19	—

Contacts

Public ContactBram van den Borst

Radboudumc

bram.vandenborst@radboudumc.nl024-3611111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)